What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 6 minute read Pharma Industry News Why Scholar Rock believes apitegromab could still become a major SMA therapy despite FDA delays Scholar Rock targets a 2026 BLA resubmission and potential launch for apitegromab in spinal muscular atrophy. Discover what it means for the SMA market. byPallavi MadhirajuMarch 4, 2026